INOVIQ Ltd Advances Breast Cancer Detection Test

Inoviq Ltd (AU:IIQ) has released an update.

INOVIQ Ltd has successfully completed disease specificity testing for its new breast cancer blood test, showcasing its ability to accurately detect breast cancer with 81% sensitivity and 93% specificity. The test outperforms existing FDA-approved tests by reducing false positives and is being developed for the US market as a laboratory-developed test. This advancement positions INOVIQ as a key player in the breast cancer diagnostics market, with plans to expand its technology to other cancer biomarkers.

For further insights into AU:IIQ stock, check out TipRanks’ Stock Analysis page.